Implicity
A Paris medtech platform for manufacturer-independent remote cardiac monitoring.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Limetax, Implicity, CloudNC — AI enters processes where errors carry real costs — Daily News 9 September 2026
Listen to the episodeAbout Implicity
Implicity aggregates and normalises data from implantable cardiac devices made by different manufacturers and organises it in a remote-monitoring platform for clinical teams. Its €35 million growth round will fund international expansion, particularly in the United States, and new heart-failure algorithms. The company reports more than 120,000 monitored patients across over 250 centres. A nationwide observational study associated use of the platform with lower mortality, but the design does not support presenting the result as definitive causal proof.
The Story
Founded in Paris in 2016 by electrophysiologist Arnaud Rosier.
How Implicity works
Business Model
B2B software for hospitals, clinics and remote cardiac-monitoring programmes.
Revenue Model
Subscriptions and contracts with healthcare providers; pricing and terms have not been disclosed.
Products & Services
Key Products
- Implicity remote monitoring platform
- IM009
- SignalHF
Core Use Cases
- Remote monitoring of implantable cardiac devices
- Cross-manufacturer data normalisation
- Prioritisation of clinical alerts
- Heart-failure monitoring
Market & Clients
Key Customers
Hospitals, clinics, cardiologists and healthcare remote-monitoring programmes.
Geographic Presence
How Implicity competes
Competitors
Competitive Advantages
- Compatibility with devices from different manufacturers
- A unified workflow for data and alerts
- Clinical data and healthcare integrations
How Implicity grows
Growth Strategy
Expand in the United States and other markets, develop heart-failure algorithms and evaluate targeted acquisitions.
Distribution Model
Direct sales and partnerships with hospitals, clinics and healthcare organisations.
Moat (Defensibility)
Device and healthcare-system integrations, longitudinal data, regulatory clearances and presence within clinical workflows.
Regulatory Context
The platform handles health data and includes medical software; clearances, surveillance, privacy, cybersecurity and clinical accountability vary by market.
Key Risks
- Generalisation of clinical results
- False positive and false negative alerts
- Interoperability across devices and systems
- Health-data privacy and security
- Reimbursement and clinical adoption
Strategic Insights
- Manufacturer independence reduces portal fragmentation for clinical teams.
- US expansion requires distribution, reimbursement and compliance in addition to algorithmic quality.
Funding & Investors
Funding Rounds
- 2026 - Growth equity: €35M
Lead: IRIS, Five Arrows
Key Investors
Founding Team
Founders
Key Metrics
Lessons from Implicity
- In healthtech, distinguishing observational association from causality protects product credibility.
- An integrated clinical workflow may be more defensible than a single predictive algorithm.
Similar Startups
Uncovr
Surgical AI startup analysing procedures to generate operative reports, coding recommendations and usable clinical records.
Read AnalysisLucis
Paris-based preventive healthcare startup analysing 110+ biomarkers and using clinically reviewed AI to guide personalised prevention.
Read AnalysisSources
- Implicity secures €35M growth equity funding — IRIS
- French cardiac monitoring startup Implicity raises €35 million — EU-Startups
- Implicity raises €35M growth funding for cardiac AI — Tech Funding News
- Impact of a universal monitoring system on outcomes of ICD patients: a nationwide study — Heart Rhythm